Bio-Techne Launches New Panel Resolving Hard-to-Decipher Carrier Screening Genes
Bio-Techne (NASDAQ: TECH) has announced the launch of the AmplideX® Nanopore Carrier Plus Kit, a genetic panel and analysis software for carrier screening research, developed in collaboration with Oxford Nanopore Technologies. The innovative kit addresses challenges in analyzing genes that are difficult to assess using conventional short-read sequencing.
The 11-gene panel includes the most prevalent recommended genes that conventional methods struggle to detect accurately. By combining AmplideX long-range PCR and nanopore long reads, the kit provides a streamlined, single-workflow solution for comprehensive sequencing data, replacing the need for multiple testing technologies like MLPA, Sanger sequencing, qPCR, and long-range PCR.
The panel targets key genes including CFTR, CYP21A2, F8 inversions, FMR1, GBA, HBA1, HBA2, HBB, SMN1, SMN2, and TNXB. This development aligns with the American College of Medical Genetics and Genomics' 2021 updated recommendations for carrier screening.
Bio-Techne (NASDAQ: TECH) ha annunciato il lancio dell'AmplideX® Nanopore Carrier Plus Kit, un pannello genetico e software di analisi per la ricerca sullo screening dei portatori, sviluppato in collaborazione con Oxford Nanopore Technologies. Questo kit innovativo affronta le sfide nell'analisi di geni che sono difficili da valutare utilizzando il sequenziamento convenzionale a lettura breve.
Il pannello di 11 geni include i geni raccomandati più prevalenti che i metodi convenzionali faticano a rilevare con precisione. Combinando AmplideX PCR a lungo raggio e letture lunghe nanopore, il kit offre una soluzione semplificata e a flusso unico per dati di sequenziamento completi, sostituendo la necessità di molteplici tecnologie di test come MLPA, sequenziamento Sanger, qPCR e PCR a lungo raggio.
Il pannello mira a geni chiave tra cui CFTR, CYP21A2, inversioni F8, FMR1, GBA, HBA1, HBA2, HBB, SMN1, SMN2 e TNXB. Questo sviluppo è in linea con le raccomandazioni aggiornate del 2021 dell'American College of Medical Genetics and Genomics per lo screening dei portatori.
Bio-Techne (NASDAQ: TECH) ha anunciado el lanzamiento del AmplideX® Nanopore Carrier Plus Kit, un panel genético y software de análisis para la investigación de detección de portadores, desarrollado en colaboración con Oxford Nanopore Technologies. Este kit innovador aborda los desafíos en el análisis de genes que son difíciles de evaluar utilizando la secuenciación convencional de lectura corta.
El panel de 11 genes incluye los genes recomendados más prevalentes que los métodos convencionales tienen dificultades para detectar con precisión. Al combinar AmplideX PCR de largo alcance y lecturas largas de nanopore, el kit proporciona una solución simplificada y de flujo único para datos de secuenciación completos, reemplazando la necesidad de múltiples tecnologías de prueba como MLPA, secuenciación Sanger, qPCR y PCR de largo alcance.
El panel se enfoca en genes clave que incluyen CFTR, CYP21A2, inversiones F8, FMR1, GBA, HBA1, HBA2, HBB, SMN1, SMN2 y TNXB. Este desarrollo está alineado con las recomendaciones actualizadas de 2021 del American College of Medical Genetics and Genomics para el screening de portadores.
Bio-Techne (NASDAQ: TECH)는 AmplideX® Nanopore Carrier Plus Kit의 출시를 발표했습니다. 이는 유전자 패널과 운반체 선별 연구를 위한 분석 소프트웨어로, Oxford Nanopore Technologies와 협력하여 개발되었습니다. 이 혁신적인 키트는 기존의 짧은 읽기 시퀀싱으로는 평가하기 어려운 유전자 분석의 과제를 해결합니다.
11개의 유전자 패널은 기존 방법으로 정확하게 탐지하기 어려운 가장 일반적인 추천 유전을 포함하고 있습니다. AmplideX 장거리 PCR과 나노포어 긴 읽기를 결합함으로써, 이 키트는 여러 테스트 기술(MLPA, Sanger 시퀀싱, qPCR 및 장거리 PCR)의 필요성을 대체하는 포괄적인 시퀀싱 데이터를 위한 단일 워크플로우 솔루션을 제공합니다.
패널은 CFTR, CYP21A2, F8 전위, FMR1, GBA, HBA1, HBA2, HBB, SMN1, SMN2 및 TNXB와 같은 주요 유전을 목표로 합니다. 이 개발은 2021년 미국 의학 유전학 및 유전체학 대학의 운반체 선별을 위한 업데이트된 권장 사항과 일치합니다.
Bio-Techne (NASDAQ: TECH) a annoncé le lancement du AmplideX® Nanopore Carrier Plus Kit, un panel génétique et un logiciel d'analyse pour la recherche sur le dépistage des porteurs, développé en collaboration avec Oxford Nanopore Technologies. Ce kit innovant répond aux défis de l'analyse de gènes difficiles à évaluer à l'aide du séquençage conventionnel à lecture courte.
Le panel de 11 gènes comprend les gènes recommandés les plus répandus que les méthodes conventionnelles ont du mal à détecter avec précision. En combinant AmplideX PCR à longue portée et des lectures longues de nanopore, le kit fournit une solution simplifiée et à flux unique pour des données de séquençage complètes, remplaçant ainsi la nécessité de plusieurs technologies de test telles que MLPA, séquençage Sanger, qPCR et PCR à longue portée.
Le panel cible des gènes clés, notamment CFTR, CYP21A2, inversions F8, FMR1, GBA, HBA1, HBA2, HBB, SMN1, SMN2 et TNXB. Ce développement est en accord avec les recommandations mises à jour en 2021 de l'American College of Medical Genetics and Genomics pour le dépistage des porteurs.
Bio-Techne (NASDAQ: TECH) hat die Einführung des AmplideX® Nanopore Carrier Plus Kit bekannt gegeben, eines genetischen Panels und einer Analyse-Software für die Forschung zur Trägerscreening, das in Zusammenarbeit mit Oxford Nanopore Technologies entwickelt wurde. Das innovative Kit adressiert Herausforderungen bei der Analyse von Genen, die mit herkömmlicher Kurzlesesequenzierung schwer zu bewerten sind.
Das 11-Gen-Paneel umfasst die am häufigsten empfohlenen Gene, die mit herkömmlichen Methoden schwer genau zu detektieren sind. Durch die Kombination von AmplideX Langstrecken-PCR und Nanopore-Langlesungen bietet das Kit eine vereinfachte, einheitliche Lösung für umfassende Sequenzierungsdaten und ersetzt die Notwendigkeit für mehrere Testtechnologien wie MLPA, Sanger-Sequenzierung, qPCR und Langstrecken-PCR.
Das Panel zielt auf Schlüsselgene ab, darunter CFTR, CYP21A2, F8-Inversionen, FMR1, GBA, HBA1, HBA2, HBB, SMN1, SMN2 und TNXB. Diese Entwicklung steht im Einklang mit den aktualisierten Empfehlungen des American College of Medical Genetics and Genomics von 2021 für das Trägerscreening.
- New product launch expanding diagnostic capabilities
- Strategic partnership with Oxford Nanopore Technologies
- Simplified workflow reducing laboratory complexity and costs
- Addresses unmet market need in carrier screening
- to research use only, not approved for clinical diagnostic use
Insights
Bio-Techne's new AmplideX® Nanopore Carrier Plus Kit represents a significant technological advancement addressing a critical pain point in genetic testing laboratories. The 11-gene panel specifically targets genes like CFTR, GBA, and SMN1 that have proven challenging to analyze with conventional methods. The timing is particularly relevant following the 2021 ACMG guideline updates that expanded carrier screening recommendations to include genes poorly suited for short-read sequencing.
The technical innovation here lies in the combination of Bio-Techne's AmplideX long-range PCR technology with Oxford Nanopore's long-read sequencing capabilities. This approach enables direct capture of large genomic variants that would otherwise require a patchwork of different techniques—MLPA, Sanger sequencing, qPCR, and others—to resolve completely. What's particularly valuable is that this consolidated workflow eliminates the complexity of running multiple assay types while actually improving data comprehensiveness.
For laboratories implementing expanded carrier screening panels, this solution could substantially streamline operations while ensuring compliance with current guidelines. The inclusion of purpose-built analysis software further reduces implementation barriers by eliminating the need for specialized bioinformatics expertise. This integrated approach reflects Bio-Techne's understanding of practical laboratory constraints beyond just technical performance.
This product launch strengthens Bio-Techne's position in the specialty diagnostics market through its Asuragen brand. The strategic partnership with Oxford Nanopore Technologies demonstrates Bio-Techne's commitment to accessing cutting-edge technologies when they provide competitive advantages—in this case, the superior long-read capabilities needed for complex genetic analysis.
The business value proposition is compelling: laboratories currently using multiple testing platforms to comply with ACMG recommendations can now consolidate their workflows, potentially reducing both operational complexity and costs. By specifically targeting "the most prevalent recommended genes that cannot be detected accurately with legacy short-read sequencing methods," Bio-Techne has focused on high-value targets where their solution offers clear differentiation.
While currently labeled for research use only, this product aligns with Bio-Techne's broader Diagnostics & Spatial Biology Segment strategy. The carrier screening market represents an established clinical need with standardized guidelines driving adoption. Dr. McManus's statement emphasizes the company's reputation for "thoughtfully designed, high-quality molecular diagnostic products," positioning this as a continuation of their brand promise rather than a deviation.
The positive commentary from Oxford Nanopore's CEO suggests a mutually beneficial relationship that could extend beyond this single product. For Bio-Techne investors, this launch demonstrates the company's ability to identify specialty market opportunities where technical differentiation can create sustainable competitive advantages.
AmplideX® Nanopore Carrier Plus Kit uses nanopore sequencing to resolve high-prevalence genes.
In 2021, the American College of Medical Genetics and Genomics (ACMG) updated its recommendations for carrier screening to include many genes that cannot be analyzed by standard short-read sequencing. In fact, half of the 10 most common genes that contribute to the risk of couples having a child with a genetic disorder are problematic for short-read sequencing. Until now, laboratories have relied on multiple test technologies, including MLPA, Sanger sequencing, qPCR, long-range PCR, and others, to analyze the recommended genes.
The AmplideX Nanopore Carrier Plus Kit addresses two problems for laboratories: it provides a single streamlined method, and it delivers comprehensive sequencing data compared to alternative assays. By combining novel AmplideX long-range PCR and nanopore long reads, it directly captures large genomic variants. The 11-gene panel includes the most prevalent recommended genes that cannot be detected accurately with legacy short-read sequencing methods, allowing labs to replace a patchwork testing approach with a single workflow to simplify sample-to-answer results. The kit also includes software to enable straightforward analysis without the need for advanced bioinformatics resources.
"Our Asuragen brand is known globally for its thoughtfully designed, high-quality molecular diagnostic products," said Dr. Matt McManus, President of Bio-Techne's Diagnostics & Spatial Biology Segment. "We chose nanopore sequencing to support the AmplideX Nanopore Carrier Plus Kit because it accurately delivers the richer data and longer reads required, making it an ideal solution for labs looking to provide superior and cost-effective carrier screening research results."
Gordon Sanghera, CEO of Oxford Nanopore Technologies, commented: "We are delighted that the Bio-Techne team recognizes the unique value of rich nanopore reads to support this important new gene panel for carrier screening research. Bio-Techne has a long and well-deserved reputation for delivering simpler and more reliable testing workflows with gold-standard reagents and kits to generate better answers. We expect this new panel will be a welcome relief for laboratory teams that have until now been forced to deploy a half-dozen or more technologies to adhere to expanded carrier screening guidelines."
The AmplideX Nanopore Carrier Plus Kit targets the following genes: CFTR, CYP21A2, F8 inversions, FMR1, GBA, HBA1, HBA2, HBB, SMN1, SMN2, and TNXB.
About Oxford Nanopore Technologies
Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for real-time, high-performance, accessible, and scalable analysis of DNA and RNA. The technology is used in more than 120 countries to understand the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses, and whole environments. Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes. For more, visit: https://nanoporetech.com/
Contact:
media@nanoporetech.com
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately
Contact:
David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-launches-new-panel-resolving-hard-to-decipher-carrier-screening-genes-302389252.html
SOURCE Bio-Techne Corporation
FAQ
What genes does Bio-Techne's AmplideX Nanopore Carrier Plus Kit (TECH) analyze?
How does Bio-Techne's new carrier screening kit (TECH) improve upon existing methods?
What is the main advantage of Bio-Techne's (TECH) new AmplideX Nanopore Carrier Plus Kit?
When will Bio-Techne's (TECH) AmplideX Nanopore Carrier Plus Kit be available?
